EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats

Yogini Patel, Sheeva Bhattarai, Céline E Toutain iD

Journal of Veterinary Pharmacology and Therapeutics · 2026-07 · 49 (4) · 353-360

DOI: 10.1111/jvp.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 11.04.2026. Verfasst von Yogini Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Elanco Animal Health, Yarrandoo R&D Centre, Kemps Creek, New South Wales, Australia. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bexagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been developed for feline diabetes mellitus. This study characterized bexagliflozin pharmacokinetics in healthy cats after single intravenous and oral administrations. Sixteen adult cats received a 1 mg/kg intravenous solution and a 15 mg oral tablet (Bexacat) in a two‐period study under fasted conditions. Serial plasma samples were collected up to 72 h and analyzed by a validated LC–MS/MS method (calibration range 1–2000 ng/mL). Pharmacokinetic parameters were derived by non‐compartmental analysis. Following intravenous dosing, bexagliflozin showed a low plasma clearance of 348 mL/h/kg. The volumes of distribution during the terminal phase ( V z ) and at steady‐state ( V SS ) were 3.5 and 1.7 L/kg, respectively. The terminal half‐life was 7.0 h. After oral dosing of the tablet, absorption was rapid (median T max 1 h; range 0.5–4 h), with C max of 1780 ng/mL and a terminal half‐life of 6.9 h. Absolute bioavailability was 78% (90% confidence interval: 73%–83%). Exposure was comparable between males and females after both routes (AUC ratios ~97%–103%). Treatments were well tolerated. These pharmacokinetic data indicate bexagliflozin exhibits rapid absorption, high oral bioavailability, and a half‐life compatible with once‐daily dosing in cats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAnimalsCatsAdministration, OralMaleFemaleHalf-LifeArea Under CurveInjections, IntravenousBiological Availability

Stichwörter der Autor:innen

SGLT2 inhibitorbexagliflozincatdiabetes mellituspharmacokinetics

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Elanco Animal Health, Yarrandoo R&D Centre, Kemps Creek, New South Wales, Australia.
  • Elanco Animal Health, Sèvres, France.

ORCID-Profile: Céline E Toutain

Zitieren

APA

Patel, Y., Bhattarai, S., & Toutain, C. E. (2026). Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats. Journal of Veterinary Pharmacology and Therapeutics, 49(4), 353-360. https://doi.org/10.1111/jvp.70072

Vancouver

Patel Y, Bhattarai S, Toutain CE. Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats. Journal of Veterinary Pharmacology and Therapeutics. 2026;49(4):353-360. doi:10.1111/jvp.70072

BibTeX
@article{Patel2026,
  author = {Patel, Yogini and Bhattarai, Sheeva and Toutain, Céline E},
  title = {Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2026},
  volume = {49},
  number = {4},
  pages = {353--360},
  doi = {10.1111/jvp.70072}
}
Kostenlos starten →